| Record ID | marc_nuls/NULS_PHC_180925.mrc:304449273:2139 |
| Source | marc_nuls |
| Download Link | /show-records/marc_nuls/NULS_PHC_180925.mrc:304449273:2139?format=raw |
LEADER: 02139cam a2200397 i 4500
001 9925310094801661
005 20180608102753.0
007 cr#cn|||||||||
008 170417s2017 sz a b 000 0 eng c
019 $a966614123
020 $a9783319524429$q(print ;$qalk. paper)
020 $a3319524429$q(print ;$qalk. paper)
035 $a(OCoLC)990156093
035 $a(OCoLC)ocn990156093
040 $aNLM$beng$erda$cNLM$dOCLCQ$dOCLCO
042 $apcc
049 $aCNUM
050 14 $aRM315$b.N476 2017
100 1 $aBAUMANN, MICHAEL H.
245 00 $aNeuropharmacology of new psychoactive substances (NPS) :$bthe science behind the headlines /$cMichael H. Baumann, Richard A. Glennon, Jenny L. Wiley, editors.
264 1 $aCham, Switzerland :$bSpringer,$c[2017]
300 $aviii, 380 pages :$billustrations (some color) ;$c25 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
490 1 $aCurrent topics in behavioral neurosciences,$x1866-3370 ;$vvolume 32
504 $aIncludes bibliographical references.
520 $aDesigner drugs, or new psychoactive substances (NPS), are synthetic chemicals that mimic the effects of classic drugs of abuse. There has been an alarming worldwide increase in the abuse of NPS in recent years. NPS are cheap, easy to obtain, and often legally available. In this volume, leading experts summarize the latest studies regarding the molecular mechanisms of action, behavioral effects, and adverse consequences of popular NPS. Specific chapters clarify the differences between various types of NPS, namely: stimulants, cannabinoids and hallucinogens. Thus, this volume broadens our understanding of NPS and provides insight into the rapidly evolving "new drug" phenomenon.
650 0 $aNeuropharmacology.
650 0 $aPsychotropic drugs.
700 1 $aBaumann, Michael H.,$eeditor.
700 1 $aGlennon, Richard A.,$d1945-$eeditor.
700 1 $aWiley, Jenny L.,$eeditor.
830 0 $aCurrent topics in behavioral neurosciences ;$v32.$x1866-3370
947 $hCIRCSTACKS$r31786103118730
980 $a99976455417